Resources
43 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 2/9/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services, through its Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), finalized modifications to the Confidentiality of Substance Use Disorder (SUD) Patient Records regulations at 42 CFR part 2 (“Part 2”), which protect the privacy of patients’ SUD treatment records.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 12/1/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) released results of the 2022 National Survey on Drug Use and Health (NSDUH). The NSDUH provides information on substance use and mental health rates in the United States with data on the self-reported use of tobacco, alcohol, and illicit drugs; substance use disorders; mental health conditions; and suicidal thoughts and behaviors. SAMSHA also released a high-level brief of the report with infographics.
Posted 11/20/2023 (updated 3/28/2024)
The U.S. Food and Drug Administration cleared the use of Alltest Fentanyl Urine Test Cassette, which is the first over-the-counter test for the preliminary detection of fentanyl in urine. The test works by placing three drops of fresh urine onto a cassette containing a fentanyl test strip. After 5 minutes the test result will appear as colored lines. Although the test does not distinguish between certain drugs and medications.
Posted 11/17/2023 (updated 3/28/2024)
Celebrate and honor the culture, traditions, and achievements of the nation's original inhabitants and of their descendants. The U.S Department of Health and Human Services (HHS) and the HHS Office of Minority Health (OMH) honor the history, culture, and legacy of Tribal nations and Indigenous communities across the United States.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 9/25/2023 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) has now added American Sign Language (ASL) services to the 988 Suicide and Crisis Lifeline. An ongoing effort of the HHS is to expand accessibility to behavioral health care for underserved communities, which includes individuals who are Deaf and Hard of Hearing.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.